[go: up one dir, main page]

WO1992001718A3 - Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 - Google Patents

Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 Download PDF

Info

Publication number
WO1992001718A3
WO1992001718A3 PCT/US1991/005059 US9105059W WO9201718A3 WO 1992001718 A3 WO1992001718 A3 WO 1992001718A3 US 9105059 W US9105059 W US 9105059W WO 9201718 A3 WO9201718 A3 WO 9201718A3
Authority
WO
WIPO (PCT)
Prior art keywords
gmp
sialyated
ligand
peptides
functionally active
Prior art date
Application number
PCT/US1991/005059
Other languages
English (en)
Other versions
WO1992001718A2 (fr
Inventor
Rodger P Mcever
Original Assignee
Univ Oklahoma Board Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma Board Of filed Critical Univ Oklahoma Board Of
Priority to AU86207/91A priority Critical patent/AU660627B2/en
Priority to CA002086323A priority patent/CA2086323C/fr
Publication of WO1992001718A2 publication Critical patent/WO1992001718A2/fr
Publication of WO1992001718A3 publication Critical patent/WO1992001718A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

On a découvert que des peptides dérivés des 3 régions de la régions de la GMP-140 se liant à la lectine entrent en intéraction sélective avec les '' sélectines'' tel que la GMP-140, l'ELAM-1 et le récepteur de nostocytose lymphocytaire. Ces 3 régions contiennent des acides aminés 19-34, 54-72 et 66-89, numérotés sur la base des numéros des restes d'acides aminés contenus dans le peptide, le reste 1 étant défini comme la terminaison N de la protéine mature après clivage du peptide signal. Des structures de lactosamines à sialyle fucosylées qui se lient à la GMP-140 ont également été découvertes. Une telle structure est créée par l'expression de α(1,3) fucosyltranférases capables de modifier les accepteurs contenant des lactosaminoglycanes substitués par acide α(2,3) sialique. L'élément Lex, Galβ1,4(Fucα1,3)GLcNAcβ1-R (où R représente une protéine ou toute autre structure à hydrate de carbone) forme le noyau de cette structure à sialyle. Ces peptides et ces structures d'hydrates de carbone sont utiles comme agents de diagnostique et dans des applications cliniques de modulation ou d'inhibition des processus de coagulation ou des processus inflammatoires.
PCT/US1991/005059 1990-07-17 1991-07-17 Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 WO1992001718A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU86207/91A AU660627B2 (en) 1990-07-17 1991-07-17 Functionally active selectin-derived peptide for GMP-140
CA002086323A CA2086323C (fr) 1990-07-17 1991-07-17 Peptides derives de la selectine actifs sur le plan fonctionnel et ligand pour gmp-140

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55419990A 1990-07-17 1990-07-17
US554,199 1990-07-17
US65048491A 1991-02-05 1991-02-05
US650,484 1991-02-05

Publications (2)

Publication Number Publication Date
WO1992001718A2 WO1992001718A2 (fr) 1992-02-06
WO1992001718A3 true WO1992001718A3 (fr) 1992-05-14

Family

ID=27070521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005059 WO1992001718A2 (fr) 1990-07-17 1991-07-17 Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140

Country Status (9)

Country Link
EP (2) EP0714912B1 (fr)
JP (5) JP3096305B2 (fr)
AT (1) ATE224911T1 (fr)
AU (2) AU660627B2 (fr)
CA (1) CA2086323C (fr)
DE (1) DE69133120T2 (fr)
DK (1) DK0714912T3 (fr)
ES (1) ES2183851T3 (fr)
WO (1) WO1992001718A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US7517980B2 (en) 2005-08-09 2009-04-14 Glycomimetics, Inc. Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
DE69029398T2 (de) * 1989-10-20 1997-04-10 New England Medical Center Inc Hemmung von padgem-vermittelter zellbindung
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) * 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
CA2108786A1 (fr) * 1991-04-19 1992-10-20 John L. Magnani Compositions et methodes de liaison endotheliale
US5817617A (en) * 1991-05-03 1998-10-06 The Rockefeller University Selectin and pertussis toxin derived peptides and uses thereof
CA2103139A1 (fr) * 1991-05-14 1992-11-15 George A. Heavner Inhibiteurs peptidiques de l'inflammation
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
CA2118695A1 (fr) * 1991-09-10 1993-03-18 George A. Heavner Inhibiteurs peptidiques de l'inflammation mediee par les selectines
WO1993005803A1 (fr) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Agents anti-inflammatoires inhibiteurs de selectines
AU3914393A (en) * 1991-12-18 1994-03-15 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation mediated by selectins
AU674317B2 (en) * 1992-04-30 1996-12-19 Genentech Inc. Lectin domain variants of selectin
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DK0642356T3 (da) * 1992-05-05 2003-08-04 Aeres Biomedical Ltd Antistoffer mod P-selectin og deres anvendelser
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
WO1993024526A1 (fr) * 1992-05-28 1993-12-09 Centocor, Inc. Peptides inhibiteurs de la liaison de selectine
CA2136428A1 (fr) * 1992-05-28 1993-12-09 George A. Heavner Inhibiteurs peptidiques de la liaison de la selectine
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
EP0666758B1 (fr) 1992-10-02 2001-12-12 Alberta Research Council Proprietes anti-inflammatoires, tolerogenes et immuno-inhibitrices de peptides de fixation d'hydrate de glucide
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
DE69333346T2 (de) * 1992-10-23 2004-10-07 Inst Genetics Llc Neuartiges p- selectin ligandenprotein
WO1994011498A1 (fr) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Ligand clycoproteique pour la p-selectine et son procede d'utilisation
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
CA2162600C (fr) 1993-05-17 2000-07-11 Chrales W. Rittershaus Compositions renfermant des proteines associees au complement recepteur et des carbohydrates; methodes de preparation et d'utilisation de ces compositions
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
WO1995014787A1 (fr) * 1993-11-22 1995-06-01 Centocor, Inc. Peptides inhibiteurs de liaison a la selectine
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2142153A1 (fr) * 1994-03-04 1995-09-05 Jacques Banville Derives .beta.-glycolipidiques sulfates, inhibiteurs de l'adherence cellulaire
WO1995030001A2 (fr) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Nouvelle proteine ligand de p-selectine
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
KR19990022954A (ko) * 1995-06-14 1999-03-25 어니스트 엠. 해데드 Ｐ-셀렉틴 리간드 및 관련 분자 및 방법
US5747463A (en) * 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
NZ333250A (en) 1996-06-10 2000-05-26 Thomas Boren Helicobacter pylori blood group antigen binding adhesion protein
PT2319928E (pt) 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
CA2580796C (fr) 2004-09-24 2013-03-26 Amgen Inc. Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2014089269A1 (fr) 2012-12-07 2014-06-12 Glycomimetics, Inc. Composés, compositions et procédés utilisant des antagonistes d'e-sélectine pour la mobilisation de cellules hématopoïétiques
PL3227310T3 (pl) 2014-12-03 2020-02-28 Glycomimetics, Inc. Heterodwufunkcyjne inhibitory selektyn E i receptorów chemokinowych CXCR4”
WO2017127422A1 (fr) 2016-01-22 2017-07-27 Glycomimetics, Inc. Inhibiteurs glycomimétiques des lectines pa-il et pa-iil
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
EP3497131B1 (fr) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
KR20240046288A (ko) 2016-10-07 2024-04-08 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
CN111201038A (zh) 2017-01-11 2020-05-26 戊瑞治疗有限公司 Psgl-1拮抗剂及其用途
PE20191708A1 (es) 2017-03-14 2019-11-28 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
CA3054605A1 (fr) 2017-03-15 2018-09-20 Glycomimetics, Inc. Derives de galactopyranosyle-cyclohexyle utilises en tant qu'antagonistes d'e-selectine
EP3717013A1 (fr) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3091454A1 (fr) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methodes de traitement de la leucemie aigue myeloide et d'etats pathologiques associes
EP3768716A1 (fr) 2018-03-21 2021-01-27 Five Prime Therapeutics, Inc. Anticorps se liant à vista à ph acide
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
EP4182700A4 (fr) * 2020-07-20 2024-11-13 Insmed Incorporated Procédés destinés à l'extraction de sérines protéases neutrophiles et de traitement de conditions induites par la dipeptidyle peptidase 1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
WO1991006632A1 (fr) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition de la liaison des cellules a mediation par padgem

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
US5030723A (en) * 1988-05-31 1991-07-09 The Biomembrane Institute Long-chain glycolipid structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
WO1991006632A1 (fr) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition de la liaison des cellules a mediation par padgem

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AM.J.RESPIR.CELL MOL.BIOL., Vol. 3, 1990 S D. Rosen: "The LEC-CAMs: An Emerging Family of Cell Adhesion Receptors Based upon Carbohydrate Recognition ", see pages 397-402, especially page 401 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 164, No. 3, 1989 M P. Skinner et al: "Characterization of human platelet GMP-140 as a heparin-binding protein ", see pages 1373-1379, especially table 1 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 172, No. 3, 1990 L Corral et al: "Requirement for sialic acid on neutrophils in a GMP-140(PADGEM) mediated adhesive interaction with activated platelets ", see pages 1349-1356, especially page 1352 and "Discussion" *
BLOOD CELLS, Vol. 16, 1990 Rodger P. McEver: "Properties of GMP-140, an Inducible Granule Membrane Protein of Platelets and Endothelium ", see pages 73-83 *
CELL, Vol. 56, 1989 G I. Johnston et al: "Cloning of GMP-140, a Granule Membrane Protein of Platelets and Endothelium: Sequence Similarity to Proteins Involved in Cell Adhesion and Inflammation ", see pages 1033-1044, in particular figure 4 and page 1039 *
CELL, Vol. 59, 1989 Eric Larsen et al: "PADGEM Protein: A Receptor That Mediates the Interaction of Activated Platelets with Neutrophils and Monocytes ", see pages 305-312 *
CELL, Vol. 63, 1990 B K. Brandley: "Carbohydrate Ligands of the LEC Cell Adhesion Molecules ", see pages 861-863, especially page 862, right-hand column - page 863 *
CELL, Vol. 63, 1990 Eric Larsen et al: "PADGEM-Dependent Adhesion of Platelets to Monocytes and Neutrophils Is Mediated by a Lineage-Specific Carbohydrate, LNF III (CD15) ", see pages 467-474, especially page 469, right-hand column *
NATURE, Vol. 343, 1990 Jian-Guo Geng et al: "Rapid neutrophil adhesion to activated endothelium mediated by GMP-140 ", see pages 757-760 *
SCIENCE, Vol. 249, 1990 Jennifer R. Gamble et al: "Prevention of Activated Neutrophil Adhesion to Endothelium by Soluble Adhesion Protein GMP140 ", see pages 414-417 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 14, 1990 David C. Ord et al: "Structure of the Gene Encoding the Human Leukocyte Adhesion Molecule-1(TQ1, Leu-8) of Lymphocytes and Neutrophils ", see pages 7760-7767, especially page 7760, right-hand column *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US7517980B2 (en) 2005-08-09 2009-04-14 Glycomimetics, Inc. Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US9534009B2 (en) 2008-04-08 2017-01-03 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
ES2183851T3 (es) 2003-04-01
AU8620791A (en) 1992-02-18
JP3096305B2 (ja) 2000-10-10
EP0714912B1 (fr) 2002-09-25
ATE224911T1 (de) 2002-10-15
WO1992001718A2 (fr) 1992-02-06
EP0544815A1 (fr) 1993-06-09
DE69133120T2 (de) 2003-05-15
AU660627B2 (en) 1995-07-06
DE69133120D1 (de) 2002-10-31
JPH11147900A (ja) 1999-06-02
JPH05509330A (ja) 1993-12-22
CA2086323C (fr) 2002-05-14
JP2001197899A (ja) 2001-07-24
EP0714912A2 (fr) 1996-06-05
EP0714912A3 (fr) 1996-06-26
CA2086323A1 (fr) 1992-01-18
AU1773195A (en) 1995-07-06
JP2005255691A (ja) 2005-09-22
DK0714912T3 (da) 2003-02-03
AU697488B2 (en) 1998-10-08
JP2004002444A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
WO1992001718A3 (fr) Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
Tanaka et al. Serine and threonine glycosidic linkages in bovine submaxillary mucin
Spiro et al. Structure of the O-glycosidically linked carbohydrate units of fetuin
Bird et al. Oligosaccharides containing fucose linked α (1–3) and α (1–4) to N-acetylglucosamine cause decompaction of mouse morulae
CA2290485A1 (fr) Procede de production de proteines non immunogenes
PT1672368E (pt) Epítopo de diagnóstico e terapêutico
CA2025598A1 (fr) Proteines d'antigene nucleocapsidique d'hepadnavirus chimerique
DE3787460D1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze.
MY102806A (en) Human interleukin-3 and muteins thereof
Hopsu-Havu et al. Formation of bradykinin from kallidin-10 by aminopeptidase B
GR3034352T3 (en) Novel polypeptides for promoting cell attachment.
NO924234L (no) Variant cd44-overflateproteiner, dna-sekvenser som koder for proteinene, antistoffer mot proteinene, samt anvendelser av proteinene i diagnose og terapi
Foltz et al. Purification and characterization of an extracellular fragment of the sea urchin egg receptor for sperm.
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
WO2000034474A3 (fr) Zvegf3 homologue du facteur de croissance
GR3030219T3 (en) LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES
Dahr et al. SDS‐polyacrylamide gel electrophoretic analysis of the membrane glycoproteins from S‐s‐U‐erythrocytes
Rosse Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome
GR3021478T3 (en) T-CEL LYMPHOMA cDNA CLONES
EP0123928A3 (fr) ADN recombinant codant pour un polypeptide présentant une activité de coagulation du lait
EP1245575A3 (fr) Peptides fonctionellement actifs dérivés de sélectine et ligand pour GMP140
Butler et al. Dentin proteins: Chemistry, structure and biosynthesis
Irving et al. Shedding of vesicular stomatitis virus soluble glycoprotein by removal of carboxy-terminal peptide
PIERCE et al. The chemistry of pituitary thyrotropin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2086323

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991916882

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916882

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991916882

Country of ref document: EP